Targeting of senescent cells with GalNP(rho) was validated in three human cancer cell lines treated with palbociclib (a selective CDK4/CDK6 inhibitor approved in combination with letrozole or fulvestrant for hormone receptor+/HER2− metastatic breast cancer; Fig 1B and Appendix Fig S1F and G). Here, CDK6 is linked to cancer.